bioAffinity Tech Q2 net loss widens to $1.7M; revenue $20k; cash $8.3M

bioAffinity Technologies, Inc.

2023-Q2 EPS reported -$0.38 revenue$3,631,208

Net loss of $1.7M ($0.20/sh) vs $88k ($0.03/sh) in Q2 2022; SG&A up to $1.4M from $409k.
Revenue of $20k, up from $1k YoY, including $10k from DOD sales of CyPath Lung.
Cash and equivalents $8.3M at June 30, 2023, down from $11.4M at Dec 31, 2022.
AMA issued CPT code for CyPath Lung effective Oct 1, 2023; DOD purchased tests.
Michael Dougherty appointed CFO; previously CFO of Amazon's Alexa commercial domains.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

bioAffinity Technologies, Inc. reported second quarter of 2023; three and six months ended June 30, 2023 results: revenue $20,000, net income $1.7 million, EPS $0.20 per share.

Period: second quarter of 2023; three and six months ended June 30, 2023
Revenue: $20,000
Net income: $1.7 million
EPS: $0.20 per share
Result: reported results

Exact text from the filing

Revenue for the second quarter of 2023 was $20,000, compared with $1,000 for the prior-year period.

View on SEC.gov

Browse all earnings releases →

bioAffinity Technologies, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-028518

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.